Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Shubham Srivastava, Bhanwar Singh Choudhary, Pakhuri Mehta, Sukanya, Manish Sharma & Ruchi Malik. (2019) Molecular dynamics insights for PI3K-δ inhibition & structure guided identification of novel PI3K-δ inhibitors. Journal of Biomolecular Structure and Dynamics 37:9, pages 2404-2414.
Read now
Read now
Scott M. Thompson, Danielle E. Jondal, Kim A. Butters, Bruce E. Knudsen, Jill L. Anderson, Matthew P. Stokes, Xiaoying Jia, Joseph P. Grande, Lewis R. Roberts, Matthew R. Callstrom & David A. Woodrum. (2018) Heat stress induced, ligand-independent MET and EGFR signalling in hepatocellular carcinoma. International Journal of Hyperthermia 34:6, pages 812-823.
Read now
Read now
Pieter H. Anborgh, Danny J. Lee, Pieter F. Stam, Alan B. Tuck & Ann F. Chambers. (2018) Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer. Expert Opinion on Therapeutic Targets 22:8, pages 727-734.
Read now
Read now
Vladimir Privman, Vyacheslav Gorshkov & Sergiy Libert. (2016) Lattice percolation approach to numerical modelling of tissue aging. International Journal of Parallel, Emergent and Distributed Systems 31:1, pages 1-19.
Read now
Read now
Corey A Carter, Ronan J Kelly & Giuseppe Giaccone. (2009) Small-molecule inhibitors of the human epidermal receptor family. Expert Opinion on Investigational Drugs 18:12, pages 1829-1842.
Read now
Read now
Tina Cascone, Erika Martinelli, Maria Pia Morelli, Floriana Morgillo, Teresa Troiani & Fortunato Ciardiello. (2007) Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. Expert Opinion on Drug Discovery 2:3, pages 335-348.
Read now
Read now
Fortunato Ciardiello, Ferdinando De Vita, Michele Orditura, Sabino De Placido & Giampaolo Tortora. (2003) Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. Expert Opinion on Emerging Drugs 8:2, pages 501-514.
Read now
Read now
Articles from other publishers (34)
Gnana Ruba Priya Muthaiah, Motamarri Venkata Naga Lalitha Chaitanya, Seema Sajjan Singh Rathore, Maida Engels S.E.Vishnu Nayak Badavath. 2023. Alternative Remedies and Natural Products for Cancer Therapy: An Integrative Approach. Alternative Remedies and Natural Products for Cancer Therapy: An Integrative Approach
139
164
.
Sobia Ahsan Halim, Sumaira Jabeen, Ajmal Khan & Ahmed Al-Harrasi. (2021) Rational Design of Novel Inhibitors of α-Glucosidase: An Application of Quantitative Structure Activity Relationship and Structure-Based Virtual Screening. Pharmaceuticals 14:5, pages 482.
Crossref
Crossref
Xiang Zhai, Richard A. Ward, Peter Doig & Argyrides Argyrou. (2020) Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies. Biochemistry 59:14, pages 1428-1441.
Crossref
Crossref
Quincy Quick. (2018) Microtubule-Actin Crosslinking Factor 1 and Plakins as Therapeutic Drug Targets. International Journal of Molecular Sciences 19:2, pages 368.
Crossref
Crossref
Hugo Monrroy, Marcelo López-Lastra & Alejandro Soza. (2017) Hepatitis C virus may have an entero-hepatic cycle which could be blocked with ezetimibe. Medical Hypotheses 102, pages 51-55.
Crossref
Crossref
C Yan, N Pattabiraman, J Goecks, P Lam, A Nayak, Y Pan, J Torcivia-Rodriguez, A Voskanian, Q Wan & R Mazumder. (2016) Impact of germline and somatic missense variations on drug binding sites. The Pharmacogenomics Journal 17:2, pages 128-136.
Crossref
Crossref
Diego Prada-Gracia, Sara Huerta-Yépez & Liliana M. Moreno-Vargas. (2016) Application of computational methods for anticancer drug discovery, design, and optimization. Boletín Médico del Hospital Infantil de México 73:6, pages 411-423.
Crossref
Crossref
Diego Prada-Gracia, Sara Huerta-Yépez & Liliana M. Moreno-Vargas. (2016) Application of computational methods for anticancer drug discovery, design, and optimization. Boletín Médico Del Hospital Infantil de México (English Edition) 73:6, pages 411-423.
Crossref
Crossref
Mohamed E.M. Saeed, Marion Meyer, Ahmed Hussein & Thomas Efferth. (2016) Cytotoxicity of South-African medicinal plants towards sensitive and multidrug-resistant cancer cells. Journal of Ethnopharmacology 186, pages 209-223.
Crossref
Crossref
Xuequn Ren, Wanli Ma, Hong Lu, Lei Yuan, Lei An, Xicai Wang, Guanchang Cheng & Shuguang Zuo. (2015) Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies. Cancer Immunology, Immunotherapy 64:12, pages 1517-1529.
Crossref
Crossref
Feng Li, Yanmei Zhang, DanYe Qiu & Jingwu Kang. (2015) Screening of epidermal growth factor receptor inhibitors in natural products by capillary electrophoresis combined with high performance liquid chromatography–tandem mass spectrometry. Journal of Chromatography A 1400, pages 117-123.
Crossref
Crossref
Yi-Chiung Hsu, Hsuan-Yu Chen, Shinsheng Yuan, Sung-Liang Yu, Chia-Hung Lin, Guani Wu, Pan-Chyr Yang & Ker-Chau Li. (2013) Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity. BMC Medicine 11:1.
Crossref
Crossref
Giuseppe Giaccone & Jean-Charles SoriaChristina Brzezniak, Corey Carter, Anish Thomas & Giuseppe Giaccone. 2013. Targeted Therapies in Oncology, Second Edition. Targeted Therapies in Oncology, Second Edition
17
50
.
Gerald Schmid-Bindert, Vittorio Gebbia, Frank Mayer, Edurne Arriola, Diego Márquez-Medina, Kostas Syrigos, Bonne Biesma, Monika Iris Leschinger, Bente Frimodt-Moller, Veronique Ripoche, Scott P. Myrand, Tuan S. Nguyen, Rebecca R. Hozak, Annamaria Zimmermann, Carla Visseren-Grul & Wolfgang Schuette. (2013) Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer. Lung Cancer 81:3, pages 428-434.
Crossref
Crossref
Daniel S. Chen & Ira Mellman. (2013) Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity 39:1, pages 1-10.
Crossref
Crossref
Ning Ding, Wei Zhang, Hua Ling Xiao, Peng Wang & Ying Xia Li. (2012) Synthesis and biological evaluation of a series of novel salicylanilides as inhibitors of EGFR protein tyrosine kinases. Chinese Chemical Letters 23:5, pages 529-532.
Crossref
Crossref
Andrean L. Simons, Kevin P. Orcutt, Joshua M. Madsen, Peter M. Scarbrough & Douglas R. Spitz. 2012. Oxidative Stress in Cancer Biology and Therapy. Oxidative Stress in Cancer Biology and Therapy
21
46
.
Ruchi Saxena & Anila Dwivedi. (2012) ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Medicinal Research Reviews 32:1, pages 166-215.
Crossref
Crossref
Jean Boucher, Linnea Olson & Bilal Piperdi. (2011) Preemptive Management of Dermatologic Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors. Clinical Journal of Oncology Nursing 15:5, pages 501-508.
Crossref
Crossref
Hanqing Li, Mengyao Li, Zaiquan Li, Liang Li, Shanshan Bi, Chenhui Deng, Rui Chen, Tianyan Zhou & Wei Lu. (2011) New Synthetic Route of Two Active Isomeric Metabolites of Erlotinib and Their Bioactivity Studies against Several Tumor Cell Lines. Chinese Journal of Chemistry 29:8, pages 1709-1714.
Crossref
Crossref
Keith M. Giles, Andrew Barker, Priscilla M. Zhang, Michael R. Epis & Peter J. Leedman. 2011. MicroRNA and Cancer. MicroRNA and Cancer
147
163
.
Matthew L. H. ChuZhaolei LangLeonard M. G. Chavas, João NeresOlga S. Fedorova, Lydia TaberneroMike CherryDavid H. WilliamsKenneth T. DouglasPatrick A. Eyers. (2010)
Biophysical and X-ray Crystallographic Analysis of Mps1 Kinase Inhibitor Complexes
,
. Biochemistry 49:8, pages 1689-1701.
Crossref
Crossref
Noboru Yamamoto, Atsushi Horiike, Yasuhito Fujisaka, Haruyasu Murakami, Tatsu Shimoyama, Yasuhide Yamada & Tomohide Tamura. (2007) Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemotherapy and Pharmacology 61:3, pages 489-496.
Crossref
Crossref
Paolo Zucali. 2007. Targeted Therapies in Oncology. Targeted Therapies in Oncology
19
44
.
Sharad S. Singhal, Yogesh C. Awasthi & Sanjay Awasthi. (2006) Regression of Melanoma in a Murine Model by RLIP76 Depletion. Cancer Research 66:4, pages 2354-2360.
Crossref
Crossref
Janine Smith. (2005) Erlotinib: Small-molecule targeted therapy in the treatmentof non-small-cell lung cancer. Clinical Therapeutics 27:10, pages 1513-1534.
Crossref
Crossref
Giuseppe Giaccone. (2005) Targeting HER1/EGFR in cancer therapy: experience with erlotinib. Future Oncology 1:4, pages 449-460.
Crossref
Crossref
Thomas Friess, Werner Scheuer & Max Hasmann. (2005) Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy. Clinical Cancer Research 11:14, pages 5300-5309.
Crossref
Crossref
Fortunato Ciardiello. (2005) Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncology 1:2, pages 221-234.
Crossref
Crossref
Fortunato Ciardiello & Ferdinando De Vita. 2005. Advances in Targeted Cancer Therapy. Advances in Targeted Cancer Therapy
93
115
.
Ray Hinerman, Weiyi Gao, Hassan H Ramadan, Cynthia Cunningham & Peilin Zhang. (2004)
Erlotinib (Tarceva
®
) inhibits oral cavity carcinoma and synergizes with cisplatin and ionizing radiation in vitro
. Therapy 1:1, pages 67-74.
Crossref
Crossref
Ray Hinerman, Weiyi Gao, Hassan H Ramadan, Cynthia Cunningham & Peilin Zhang. (2004) Erlotinib (TarcevaR) inhibits oral cavity carcinoma and synergizes with cisplatin and ionizing radiation in vitro. Therapy 1:1, pages 67-74.
Crossref
Crossref
Joan Albanell Mestres, Montserrat Muñoz Mateo & Pedro Gascón. (2004) ErbB tyrosine kinase receptor inhibitors in breast cancer treatmentInhibidores del receptor ErbB de tirosina quinase en el tratamiento del cáncer de mama. Revista de Oncología 6:1, pages 12-21.
Crossref
Crossref
Maarten L. Janmaat & Giuseppe Giaccone. (2003) Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. The Oncologist 8:6, pages 576-586.
Crossref
Crossref